11:19 AM EST - Theratechnologies Inc. : Today presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in reducing HIV RNA to undetectable levels in heavily treatment-experienced (HTE) patients with multidrug resistant HIV. Theratechnologies Inc.
shares T.TH are trading up $0.03 at $2.21.
